polycystic kidney disease
polycystic kidney disease
Explore linked clinical trials. Standard reference: MONDO:002064268 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Not yet recruiting | Phase 1 | 2026-10-09 | NCT07868926 | |
| ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 2 | 2026-10-06 | NCT06902558 | |
| Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 1 | 2026-09-30 | NCT07792408 | |
| Bempedoic Acid Therapy for Polycystic Kidney Disease | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 2 | 2026-09-29 | NCT07282821 | |
| ADPKD Patient Registry | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Not stated | 2026-09-22 | NCT04039061 | |
| Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Active, not recruiting | Phase 2 | 2026-09-21 | NCT07161037 | |
| Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 1 | 2026-09-11 | NCT07228364 | |
| Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Active, not recruiting | Not stated | 2026-09-09 | NCT06747572 | |
| A Phase 1 Study of Single and Multiple Ascending Doses of GV-100 | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 1 | 2026-08-26 | NCT07788014 | |
| HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Polyuria, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 3 | 2026-08-25 | NCT05373264 | |
| Managing Depressive Symptoms in ADPKD | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Not applicable | 2026-08-07 | NCT07745920 | |
| A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Polycystic Kidney, Autosomal Recessive, Urogenital Diseases, cystic kidney disease, hereditary disease, kidney disorder, oligohydramnios, polycystic kidney disease, pregnancy disorder, urinary system disorder | Recruiting | Phase 3 | 2026-08-07 | NCT04782258 | |
| A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Active, not recruiting | Phase 1 | 2026-07-30 | NCT06734234 | |
| STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 3 | 2026-07-28 | NCT07280585 | |
| Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 1 | 2026-07-27 | NCT06714006 | |
| Dietary Modulation of Urinary MCP-1 in ADPKD | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Not yet recruiting | Not applicable | 2026-06-26 | NCT07651397 | |
| Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Not stated | 2026-06-15 | NCT04338048 | |
| ARPKD Database Study | Abnormalities, Multiple, Agenesis of Cerebellar Vermis, Bardet-Biedl syndrome, Caroli disease, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Abnormalities, Digestive System Diseases, Eye Diseases, Hereditary, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Meckel syndrome, type 1, Polycystic Kidney, Autosomal Recessive, Urogenital Diseases, bile duct cyst, bile duct disorder, biliary tract disorder, brain disorder, central nervous system disorder, cystic kidney disease, eye disorder, hereditary disease, hypothalamic disorder, isolated congenital hepatic fibrosis, kidney disorder, nephronophthisis, nephronophthisis 1, nervous system disorder, polycystic kidney disease, retinitis pigmentosa, urinary system disorder | Recruiting | Not stated | 2026-06-15 | NCT01401998 | |
| A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, autosomal dominant polycystic liver disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-06-01 | NCT05281328 | |
| Well-Formulated Ketogenic Diet Polycystic Kidney Disease | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Not applicable | 2026-05-14 | NCT06325644 | |
| Renal Denervation in ADPKD- RDN-ADPKD Study | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Active, not recruiting | Not applicable | 2026-05-05 | NCT05460169 | |
| Drug-Drug Interactions of JMKX003142 in Healthy Participants | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Not yet recruiting | Phase 1 | 2026-05-04 | NCT07565441 | |
| Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Active, not recruiting | Not applicable | 2026-05-01 | NCT06496542 | |
| Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Active, not recruiting | Phase 2 | 2026-05-01 | NCT05510115 | |
| The German ADPKD Tolvaptan Treatment Registry | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Not stated | 2026-04-30 | NCT02497521 |